← Back
Data updated: Mar 10, 2026
SYNDAX
OncologyRespiratory
SYNDAX is a pharmaceutical company focused on Oncology, Respiratory. Key products include REVUFORJ.
2024
Since
1
Drugs
-
Trials
2
Approved (2yr)
Recent Activity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 92%
1 drugs Phase 3: 1 Phase 1: 12
Respiratory 8%
0 drugs Phase 2: 1
Pipeline Strength Pro
Loading...
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-11-15
- Latest
- 2025-10-24
- Applications
- 1